Lipocine (LPCN) Revenue & Revenue Breakdown
Lipocine Revenue Highlights
Latest Revenue (Y)
$11.20M
Latest Revenue (Q)
$622.85K
Main Segment (Y)
Royalty
Lipocine Revenue by Period
Lipocine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $11.20M | -492.80% |
| 2023-12-31 | $-2.85M | -670.16% |
| 2022-12-31 | $500.00K | -96.90% |
| 2021-12-31 | $16.14M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $164.99K | -61.45% |
| 2018-12-31 | $428.03K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2012-12-31 | $7.71M | 100.00% |
| 2011-12-31 | - | - |
Lipocine generated $11.20M in revenue during NA 2024, up -492.80% compared to the previous quarter, and up 6787.17% compared to the same period a year ago.
Lipocine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $622.85K | 563.57% |
| 2025-03-31 | $93.86K | -97.31% |
| 2024-12-31 | $3.49M | 100.00% |
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $89.56K | -98.82% |
| 2024-03-31 | $7.62M | 3423.40% |
| 2023-12-31 | $216.19K | -106.92% |
| 2023-09-30 | $-3.12M | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $54.99K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $500.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $16.09M | 29150.18% |
| 2021-09-30 | $54.99K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $164.99K | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $428.03K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $13.50M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | - |
Lipocine generated $622.85K in revenue during Q2 2025, up 563.57% compared to the previous quarter, and up 8.18% compared to the same period a year ago.
Lipocine Revenue Breakdown
Lipocine Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Royalty | $298.14K | - | - | - |
| License | - | $109.99K | $500.00K | $11.00M |
| Sales-based royalties | - | - | - | $54.99K |
| Minimum guaranteed royalties | - | - | - | $4.05M |
| Materials | - | - | - | $1.04M |
Latest
Lipocine's latest annual revenue breakdown by segment (product or service), as of Dec 24: Royalty (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 |
|---|---|---|
| License | $500.00K | - |
| Reportable Segment | - | $93.86K |
Latest
Lipocine's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License (100.00%).
Lipocine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| LPCN | Lipocine | $11.20M | $622.85K |
| DARE | Daré Bioscience | $9.78M | $25.43K |
| PULM | Pulmatrix | $7.81M | - |
| ANL | Adlai Nortye Ltd. American Depositary Shares | $5.00M | $2.50M |
| LEXX | Lexaria Bioscience | $464.28K | $174.00K |
| EDSA | Edesa Biotech | - | - |
| ASBP | Aspire Biopharma | - | - |
| GNPX | Genprex | - | - |
| NERV | Minerva Neurosciences | - | - |
| FBLG | FibroBiologics | - | - |